Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. CSL Limited
  6. Summary
    CSL   AU000000CSL8

CSL LIMITED

(CSL)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Australian Stock Exchange
07/19/2021 07/20/2021 07/21/2021 07/22/2021 07/23/2021 Date
282.74 286.48 290.13 289.24 293.48 Last
656467 656499 681930 461915 522811 Volume
+1.81% +1.32% +1.27% -0.31% +1.47% Change
Estimated financial data (e) (USD)
Sales 2021 10 110 M - -
Net income 2021 2 327 M - -
Net Debt 2021 4 148 M - -
P/E ratio 2021 42,3x
Yield 2021 0,94%
Sales 2022 10 537 M - -
Net income 2022 2 357 M - -
Net Debt 2022 3 932 M - -
P/E ratio 2022 41,8x
Yield 2022 1,03%
Capitalization 98 362 M 98 446 M -
EV / Sales 2021 10,1x
EV / Sales 2022 9,71x
Nbr of Employees 27 000
Free-Float 99,8%
More Financials
Company
CSL Limited is an Australia-based biotechnology company engaged in the developing and delivering medicines that treat people with rare diseases. It offers treatments for people who are living with conditions in the immunology and neurology; haematology and thrombosis; cardiovascular and metabolic; respiratory, and transplant therapeutic areas. Its segment includes CSL Behring and Seqirus. CSL Behring segment... 
Sector
Pharmaceuticals
Calendar
08/18Earnings Release
More about the company
Ratings of CSL Limited
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
A-
More Ratings
All news about CSL LIMITED
07/23Australian shares end at record high on healthcare, tech boost
RE
07/20Australia shares extend losses as miners and energy stocks weigh, Oil Search ..
RE
07/16Australia shares log best week in six as BHP hits record high
RE
07/15Australian shares edge lower as lockdowns weigh
RE
07/07Australian shares close at 2-week high on IT, health stocks boost
RE
07/06Australian shares rise on healthcare, tech boost; Challenger shines
RE
06/25CSL Limited Announces Resignation of Abbas Hussain as Independent Non-Executi..
CI
06/23Australia shares dragged by banks, energy stocks amid NSW virus concerns
RE
06/18Australia shares end higher on tech, healthcare boost
RE
06/15CSL Limited Appoints Alison Watkins as an Independent Non-Executive Director,..
CI
06/09Australian shares inch higher on tech gains; U.S. inflation data eyed
RE
06/09CSL : Hizentra (Immune Globulin Subcutaneous 20% Liquid) To Be Covered Under Med..
AQ
06/08Australia shares off record peak as focus shifts to U.S. data
RE
06/04Financials lift Aussie stocks to all-time high for third day on GDP data boos..
RE
05/31CSL : Applications Open for Fellowships
PU
More news
News in other languages on CSL LIMITED
05/05MÄRKTE ASIEN/Schwache US-Vorgaben dämpfen Kauflaune
04/09Australia duplica el pedido de vacunas de Pfizer tras el revés de AstraZeneca
04/07SCOTT MORRISON : L'Australie appelle l'UE à livrer des vaccins, si blocage il n'..
04/06ASTRAZENECA : L'Australie appelle l'UE à livrer des vaccins, si blocage il n'y a..
04/06ASTRAZENECA : L'Australie dit que l'UE lui a demandé de retirer sa demande d'exp..
More news
Analyst Recommendations on CSL LIMITED
More recommendations
Chart CSL LIMITED
Duration : Period :
CSL Limited Technical Analysis Chart | CSL | AU000000CSL8 | MarketScreener
Technical analysis trends CSL LIMITED
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 14
Last Close Price 216,12 $
Average target price 228,77 $
Spread / Average Target 5,86%
EPS Revisions
Managers and Directors
Paul Roger Perreault Chief Executive Officer, Executive Director & MD
Joy Carolyn Linton Chief Financial Officer
Brian Anthony McNamee Chairman
Andrew Cuthbertson Chief Scientific Officer & Executive Director
William Mezzanotte Chief Medical Officer, EVP & Head-R&D
Sector and Competitors